Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction

29 August 2025 (07:00 - 18:00)

Organised by:

About the speaker

Doctor Nils Kruger

Brigham and Women's Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail

CONFIDENCE: Results by KDIGO risk category

Doctor M. Vaduganathan (Boston, US)

Presentation thumbnail

SGLT2i and AF

Doctor J. Sedighi (Giessen, DE)

Presentation thumbnail

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

Professor M. Mamas (Keele, GB)

Presentation thumbnail

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Ms L. Wilson (US)

Presentation thumbnail

STRIDE Outcomes by Sexl

Professor S. Verma (Toronto, CA)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Newer GLP-1 receptor agonists and clinical outcomes in heart failure with reduced ejection fraction: a real-world comparative study

Congress Presentation

PRAISE-HFrEF: Glucagon-like peptide-1 receptor agonism in heart failure with reduced ejection fraction and obesity

Congress Presentation

Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources